新聞/Reuters/Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thro…Pharmaessentia Announces Positive Topline Phase 2B Data From Exceed-Et Study Evaluating Ropeginterferon Alfa-2B-Njft For Essential Thrombocythemia閱讀全文無限制訪問Reuters以及TradingView所有其他新聞來源的文章。繼續閱讀